Remdesivir in adults with severe COVID-19
a randomised, double-blind, placebo-controlled, multicentre trial
Wang, Yeming
Zhang, Dingyu
Du, Guanhua
Du, Ronghui
Zhao, Jianping
Jin, Yang
Fu, Shouzhi
Gao, Ling
Cheng, Zhenshun
Lu, Qiaofa
Wang, Ke
Lu, Yang
Li, Huadong
Wang, Shuzhen
Ruan, Shunan
Yang, Chengqing
Mei, Chunlin
Wang, Yi
Ding, Dan
Wu, Feng
Tang, Xin
Ye, Xianzhi
Ye, Yingchun
Liu, Bing
Yang, Jie
Yin, Wen
Wang, Aili
Fan, Guohui
Zhou, Fei
Liu, Zhibo
Gu, Xiaoying
Xu, Jiuyang
Shang, Lianhan
Zhang, Yi
Cao, Lianjun
Guo, Tingting
Wan, Yan
Qin, Hong
Jiang, Yushen
Jaki, Thomas
Hayden, Frederick G.
Horby, Peter W.
Cao, Bin
Wang, Chen
text
ph
monographic
eng
Yeming Wang [and forty one others]
In: The Lancet, 2020 Vol. 395 (10236) page 1569-1578
Nucleosides
Prodrugs
Coronavirus
Remdesivir
COVID-19
https://www.thelancet.com/action/showPdf?pii=S0140-6736%2820%2931022-9
https://www.thelancet.com/action/showPdf?pii=S0140-6736%2820%2931022-9
200528
20200806155507.0
D0001C000035